Business Description
RenovoRx Inc
NAICS : 541714
SIC : 2834
ISIN : US75989R1077
Total Employee Number:
17Description
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 24.31 | |||||
Equity-to-Asset | 0.78 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 4.66 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 31.5 | |||||
3-Year EPS without NRI Growth Rate | 31.8 | |||||
3-Year FCF Growth Rate | 31.6 | |||||
3-Year Book Growth Rate | -39.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 208.9 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 74.69 | |||||
9-Day RSI | 70.7 | |||||
14-Day RSI | 68.82 | |||||
3-1 Month Momentum % | -5.51 | |||||
6-1 Month Momentum % | 0.03 | |||||
12-1 Month Momentum % | -6.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.74 | |||||
Quick Ratio | 5.53 | |||||
Cash Ratio | 5.03 | |||||
Days Inventory | 362.33 | |||||
Days Sales Outstanding | 52.87 | |||||
Days Payable | 1024.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -59.1 | |||||
Shareholder Yield % | -15.63 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 84.41 | |||||
Operating Margin % | -685.27 | |||||
Net Margin % | -621.71 | |||||
EBITDA Margin % | -684.92 | |||||
FCF Margin % | -600.51 | |||||
OCF Margin % | -600.51 | |||||
ROE % | -138.39 | |||||
ROA % | -105.22 | |||||
ROIC % | -1514.65 | |||||
3-Year ROIIC % | -441.55 | |||||
ROC (Joel Greenblatt) % | -4899.06 | |||||
ROCE % | -137.68 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 31.72 | |||||
PB Ratio | 7.45 | |||||
Price-to-Tangible-Book | 7.4 | |||||
EV-to-EBIT | -4.29 | |||||
EV-to-EBITDA | -4.3 | |||||
EV-to-Revenue | 29.43 | |||||
EV-to-Forward-Revenue | 13.69 | |||||
EV-to-FCF | -4.9 | |||||
| Price-to-Net-Current-Asset-Value | 8.22 | |||||
| Price-to-Net-Cash | 9.87 | |||||
Earnings Yield (Greenblatt) % | -23.31 | |||||
FCF Yield % | -17.65 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:RNXT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
RenovoRx Inc Executives
DetailsGF Value™
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.976 | ||
| EPS (TTM) ($) | -0.31 | ||
| Beta | 2.2178 | ||
| 3-Year Sharpe Ratio | 0.23 | ||
| 3-Year Sortino Ratio | 0.74 | ||
| Volatility % | 61.28 | ||
| 14-Day RSI | 68.82 | ||
| 14-Day ATR ($) | 0.126794 | ||
| 20-Day SMA ($) | 1.194475 | ||
| 12-1 Month Momentum % | -6.33 | ||
| 52-Week Range ($) | 0.7006 - 1.56 | ||
| Shares Outstanding (Mil) | 45.13 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
RenovoRx Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
RenovoRx Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 79 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 78 days | ||
| The Evolving Pancreatic Cancer Landscape: The Role of RenovoRx\'s TAMP Platform and Emerging Clinical Advances | 2026-08-13 13:30 | 1.12 (-1.75%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 16:30 | 1.15 (-0.86%) | ||
| Second quarter earnings results for 2026 | 2026-08-12 | 1.15 (-0.86%) | ||
| General meeting for 2026 | 2026-06-30 09:00 | 0.97 (+3.50%) | ||
| iAccess Alpha Virtual Conference Details | 2026-06-23 12:30 | 0.91 (-1.07%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 16:30 | 0.85 (-3.59%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 0.85 (-3.59%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-30 16:30 | 1.13 (-1.74%) |
Show
Entries
RenovoRx Inc Frequently Asked Questions
What is RenovoRx Inc(RNXT)'s stock price today?
The current price of RNXT is $1.48. The 52 week high of RNXT is $1.56 and 52 week low is $0.70.
When is next earnings date of RenovoRx Inc(RNXT)?
The next earnings date of RenovoRx Inc(RNXT) is 2026-11-13 Est..
Does RenovoRx Inc(RNXT) pay dividends? If so, how much?
RenovoRx Inc(RNXT) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers